Details

Autor(en) / Beteiligte

• Mahdaviani, Seyed Alireza
• Fallahi, Mazdak
• Jamee, Mahnaz
• Marjani, Majid
• Tabarsi, Payam
• Moniri, Afshin
• Farnia, Parisa
• Daneshmandi, Zahra
• Parvaneh, Nima
• Casanova, Jean-Laurent
• Bustamante, Jacinta
• Mansouri, Davood
• Velayati, Ali Akbar

Titel

Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series

Ist Teil von

• Annals of clinical microbiology and antimicrobials, 2022-03, Vol.21 (1), p.8-8, Article 8

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2022

Quelle

SpringerLink

Beschreibungen/Notizen

• Post-vaccination BCG disease typically attests to underlying inborn errors of immunity (IEIs), with the highest rates of complications in patients with Mendelian susceptibility to mycobacterial disease (MSMD). However, therapeutic protocols for the management of BCG-osis (disseminated) and persistent BCG-itis (localized) are still controversial. Twenty-four Iranian patients with MSMD (BCG-osis or BCG-itis), followed from 2009 to 2020 in Tehran, were included in the study. Their medical records were retrospectively reviewed for demographics, clinical features, laboratory findings, and molecular diagnosis. The therapeutic protocol sheets were prepared to contain the types and duration of anti-mycobacterial agents. BCG disease either as BCG-itis (33.3%) or BCG-osis (66.7%) was confirmed in all patients by positive gastric washing test (54.2%), microbial smear and culture (58.3%), or purified protein derivative (PPD) test (4.2%). The duration between BCG-osis onset and MSMD diagnosis was 21.6 months. All except three patients were initiated on second-line anti-mycobacterial agents with either a fluoroquinolone (levofloxacin: 15 mg/kg/day, ciprofloxacin: 20 mg/kg/day, ofloxacin: 15 mg/kg/day), aminoglycoside (amikacin: 10-15 mg/kg/day, streptomycin: 15 mg/kg/day), and/or macrolide (clarithromycin: 15 mg/kg/day) along with oral rifampin (10 mg/kg/day), isoniazid (15 mg/kg/day), and ethambutol (20 mg/kg/day). Three patients showed a clinical response to rifampin, despite in vitro resistance. Fourteen (58.3%) patients received also adjuvant subcutaneous IFN-γ therapy, 50 µ/m every other day. At the end of survey, most patients (n = 22, 91.7%) were alive and two patients died following BCG-osis and respiratory failure. We recommend the early instigation of second-line anti-mycobacterial agents in MSMD patients with BCG disease.